Literature DB >> 24661223

Novel effect of the inhibitor of mitochondrial cyclophilin D activation, N-methyl-4-isoleucine cyclosporin, on renal calcium crystallization.

Kazuhiro Niimi1, Takahiro Yasui, Atsushi Okada, Yasuhiko Hirose, Yasue Kubota, Yukihiro Umemoto, Noriyasu Kawai, Keiichi Tozawa, Kenjiro Kohri.   

Abstract

OBJECTIVES: To experimentally evaluate the clinical application of N-methyl-4-isoleucine cyclosporin, a novel selective inhibitor of cyclophilin D activation.
METHODS: In vitro, cultured renal tubular cells were exposed to calcium oxalate monohydrate crystals and treated with N-methyl-4-isoleucine cyclosporin. The mitochondrial membrane was stained with tetramethylrhodamine ethyl ester perchlorate and observed. In vivo, Sprague-Dawley rats were divided into four groups: a control group, an ethylene glycol group (administration of ethylene glycol to induce renal calcium crystallization), a N-methyl-4-isoleucine cyclosporin group (administration of N-methyl-4-isoleucine cyclosporin) and an ethylene glycol + N-methyl-4-isoleucine cyclosporin group (administration of ethylene glycol and N-methyl-4-isoleucine cyclosporin). Renal calcium crystallization was evaluated using Pizzolato staining. Oxidative stress was evaluated using superoxide dismutase and 8-hydroxy-deoxyguanosine. Mitochondria within renal tubular cells were observed by transmission electron microscopy. Cell apoptosis was evaluated using cleaved caspase-3.
RESULTS: In vitro, calcium oxalate monohydrate crystals induced depolarization of the mitochondrial membrane potential, which was remarkably prevented by N-methyl-4-isoleucine cyclosporin. In vivo, ethylene glycol administration induced renal calcium crystallization, oxidative stress, mitochondrial collapse and cell apoptosis in rats, which were significantly prevented by N-methyl-4-isoleucine cyclosporin.
CONCLUSIONS: Herein we first report a new treatment agent determining renal calcium crystallization through cyclophilin D activation.
© 2014 The Japanese Urological Association.

Entities:  

Keywords:  N-methyl-4-isoleucine cyclosporin; cyclophilin D; oxidative stress; renal calcium crystallization; renal tubular cell injury

Mesh:

Substances:

Year:  2014        PMID: 24661223     DOI: 10.1111/iju.12425

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  Mitochondria Permeability Transition versus Necroptosis in Oxalate-Induced AKI.

Authors:  Shrikant Ramesh Mulay; Mohsen M Honarpisheh; Orestes Foresto-Neto; Chongxu Shi; Jyaysi Desai; Zhi Bo Zhao; Julian A Marschner; Bastian Popper; Ewa Miriam Buhl; Peter Boor; Andreas Linkermann; Helen Liapis; Rostyslav Bilyy; Martin Herrmann; Paola Romagnani; Ilya Belevich; Eija Jokitalo; Jan U Becker; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2019-07-11       Impact factor: 10.121

2.  Deregulated MTOR (mechanistic target of rapamycin kinase) is responsible for autophagy defects exacerbating kidney stone development.

Authors:  Rei Unno; Tsuyoshi Kawabata; Kazumi Taguchi; Teruaki Sugino; Shuzo Hamamoto; Ryosuke Ando; Atsushi Okada; Kenjiro Kohri; Tamotsu Yoshimori; Takahiro Yasui
Journal:  Autophagy       Date:  2019-06-29       Impact factor: 16.016

Review 3.  The Molecular Aspect of Nephrolithiasis Development.

Authors:  Paulina Wigner; Radosław Grębowski; Michal Bijak; Janusz Szemraj; Joanna Saluk-Bijak
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

4.  Vorinostat protects against calcium oxalate-induced kidney injury in mice.

Authors:  Li Wang; Wei Chen; Zhongjiang Peng; Changcheng Liu; Caihong Zhang; Zhiyong Guo
Journal:  Mol Med Rep       Date:  2015-06-19       Impact factor: 2.952

5.  Size-dependent cellular uptake mechanism and cytotoxicity toward calcium oxalate on Vero cells.

Authors:  Xin-Yuan Sun; Qiong-Zhi Gan; Jian-Ming Ouyang
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

Review 6.  Mitochondrial Dysfunction and Kidney Stone Disease.

Authors:  Sakdithep Chaiyarit; Visith Thongboonkerd
Journal:  Front Physiol       Date:  2020-10-20       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.